Nuron Biotech nabs $80M from HealthCare Royalty Partners

Just days after snagging Pfizer's ($PFE) meningitis, sepsis and pneumonia vaccine, Nuron Biotech landed an $80 million deal to further elevate its expanding porfolio of vaccines. HealthCare Royalty Partners II will invest $30 million in the company, with an additional $50 million for a royalty pact based on sales of its vaccines. Nuron has spent the past few years building a market for vaccines; the company acquired Pfizer's Hib vaccine last year and is developing a pipeline of new chemical entities. Story | Release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.